CNS Demyelination with TNF-α Blockers

Tumor necrosis factor–α (TNF-α) blockers are a popular therapeutic choice in a number of inflammatory diseases. Thus far, five TNF- α blockers have been approved for clinical use (etanercept, infliximab, adalimumab, golimumab. and certolizumab). Despite being considered relatively safe, serious side...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemanetzoglou, Elissavet, Andreadou, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Demyelinating Disorders (D N Bourdette & M Cameron, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364240/
https://www.ncbi.nlm.nih.gov/pubmed/28337644
http://dx.doi.org/10.1007/s11910-017-0742-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364240/
https://www.ncbi.nlm.nih.gov/pubmed/28337644
http://dx.doi.org/10.1007/s11910-017-0742-1

Ejemplares similares